The EBS-B study was sponsored by the ERP Biomarker Qualification Consortium, whose membership includes; Merck, Novartis, AbbVie, Astellas, Lundbeck, Anavex, Sage, Alkermes, Neurocrine, and Takeda. The Consortium is dedicated to performing "precompetitive" studies in neuro-related areas that provide results that benefit large near-term drug programs. These results might include quantification of brain-related deficits that can ...
The EBS-B study was sponsored by the ERP Biomarker Qualification Consortium, whose membership includes; Merck, Novartis, AbbVie, Astellas, Lundbeck, Anavex, Sage, Alkermes, Neurocrine, and Takeda. The Consortium is dedicated to performing "precompetitive" studies in neuro-related areas that provide results that benefit large near-term drug programs. These results might include quantification of brain-related deficits that can be used as drug targets, quantification of the brain effects of well-understood compounds, or development of normative databases of brain-based biomarkers.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.